bioRxivNeurosciencePreprint
Metabolic brain network reorganization precedes clinical conversion in Alzheimer's disease
Christian LimbergeriD, Guilherme Garcia Schu, Giordana Salvi de SouzaiD, Marco Antônio De BastianiiD, Andrei BiegeriD, Gabriel Bueno MartinsiD, Giovanna Carello‐CollariD, Guilherme PovalaiD, Luiza Santos MachadoiD, Thomas Hugentobler SchlickmanniD, Alzheimer’s Disease Neuroimaging Initiative, Tharick Ali PascoaliD, Pedro Rosa‐NetoiD, Débora G. de Souza, Eduardo Rigon ZimmeriD
Abstract
Structured AbstractO_ST_ABSIntroductionC_ST_ABSBrain glucose hypometabolism is a hallmark of Alzheimers disease (AD), yet conventional [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) analyses have limited sensitivity in preclinical stages. Metabolic brain network approaches may better capture early vulnerability preceding clinical conversion. MethodsCognitively unimpaired individuals (n = 127) from the ADNI cohort with baseline FDG-PET and amyloid (A) and tau (T) status were classified as clinically stable or converters over an average longitudinal follow-up of 5.8 years. Baseline brain FDG uptake patterns were analyzed at the regional, voxel, and network levels across AT profiles. Network density was quantified globally and within functional networks. AD biomarkers and cognitive performance were also examined. ResultsConventional FDG-PET SUVr analyses failed to distinguish cognitively stable individuals from clinical converters at baseline, either at the regional or voxel levels. AT(N) biomarkers and neuropsychological performance likewise did not differ significantly between groups. In contrast, clinical converters exhibited hyperconnected metabolic networks at baseline, including within the default-mode network. These effects were consistent across A-T-, A+T-, and A+T+ groups, with network density higher in clinical converters than in cognitively stable individuals. Conversely, network density among stable individuals declined with AT progression, pointing to divergent network trajectories. DiscussionMetabolic network organization analysis revealed early AD-related vulnerability beyond regional hypometabolism, even before detectable amyloid positivity, and may reflect divergent trajectories of resilience and pathological propagation preceding clinical conversion. By leveraging existing FDG-PET datasets, this framework offers a valuable opportunity to identify individuals at risk of clinical progression at scale.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Brain Metabolic Network Covariance and Aging in a Mouse Model of Alzheimer's Disease
Evgeny J. Chumin, Charles P. Burton, … Paul R. Territo·Alzheimer s & DementiaPeer-reviewed·Nov 30, 2023
- Multiscale Metabolic Covariance Networks Uncover Stage-Specific Biomarker Signatures Across the Alzheimer's Disease Continuum.
Juan Antonio K. Chong Chie, Scott A. Persohn, … Alzheimer’s Disease Neuroimaging Initiative·Alzheimer s & DementiaPeer-reviewed·Apr 1, 2026
- 18F-FDG-PET Hyperactivity in Alzheimers Disease Cerebellum and Primary Olfactory Cortex
Mark D. Meadowcroft, Carson J. Purnell, … The Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·Jun 5, 2020
- Stage dependent differential influence of metabolic and structural networks on memory across Alzheimer's disease continuum
Kok Pin Ng, Xing Qian, … the Alzheimer’s Disease Neuroimaging Initiative·eLifePeer-reviewed·Sep 2, 2022
- Graph analysis of structural brain networks in Alzheimer’s disease
Majnu John, Toshikazu Ikuta, Janina D Ferbinteanu·Brain Structure and FunctionPeer-reviewed·Jun 29, 2016
- Alterations in resting-state network dynamics along the Alzheimer's disease continuum: a combined MEG-PET/MR approach
Delphine Puttaert, Nicolas Coquelet, … Xavier De Tiège·bioRxiv·May 18, 2020